Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDIV

Sponsor class

Conditions

Drug; Withdrawal Symptoms, Neonatal
Withdrawal
Fetus and Newborn Affected by Other Maternal Medication

Interventions

DRUG: BZDs + opiate exposure treated with BPN
DRUG: Opiates exposure treated with BPN

Sponsor

Gauda, Estelle B., M.D.

Collaborators

[object Object]
[object Object]